A Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects.
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2015
At a glance
- Drugs ONO 2952 (Primary)
- Indications Irritable bowel syndrome
- Focus Adverse reactions
- Acronyms MAD
- 03 Aug 2015 Results of MAD and SAD study published in the Clinical Therapeutics.
- 31 Jul 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
- 29 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.